|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG007471181 |
003 |
DE-627 |
005 |
20230425173035.0 |
007 |
cr uuu---uuuuu |
008 |
210512s2023 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)CTG007471181
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2020-006003-42-DK
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)ENFORCE
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a Same as above
|b National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE) - ENFORCE
|
264 |
|
1 |
|c 2023
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 21-12-2020, Last updated: 2023-02-02
|
650 |
|
4 |
|a Medical Condition: The aim is to study primarily effectiveness as well as safety of citizens being vaccinated with one of the SARS-CoV2 vaccines being applied in the Danish COVID-19 vaccine programme. Whereas ongoing phase III trials are reporting vaccine efficacy in defined study populations, the effectiveness of these vaccines – and in particular the durability hereof - once introduced into the general population is presently unknown, and the focus of intense research and public health interest. MedDRA version: 23.1Level: LLTClassification code 10084465Term: COVID-19 vaccinationSystem Organ Class: 100000004865;Therapeutic area: Health Care [N] - Environment and Public Health [N06]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 4
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 30. Jan.
|
773 |
1 |
8 |
|g year:2023
|g day:30
|g month:01
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-006003-42
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2023
|b 30
|c 01
|